transferred on share sale and purchase date from the seller’s connected persons ) and related services i.e. registration with Food and Drug Administration (FDA), trademark permission, product and packaging
. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
”) Retail Finance 100% General characteristics of transactions: 1. AEONTS provides the support on the business operation including marketing research and support as well as system support to ACS Capital, and
last year. Selling and administrative expenses (including research and development – R&D) in Q1’19 went up 16.7% from Q1’18 and keep close to Q4’18 due to the R&D and sales force invested in order to
year and 23.0% in last quarter this year. Selling and administrative expenses (including research and development – R&D) in Q2’19 went up 21.0% from Q2’18 and up 5.8% from Q1’19 due to R&D and sales
drop to 19.1%, compare to 24.5% in the same quarter of last year and 19.9% in last quarter. Selling and administrative expenses (including research and development – R&D) in Q3’19 went up 5.7% from Q3’18